Yuan Mi

This inventor holds 23 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Novartis Ag, Irm LLC, Cytosinlab Therapeutics Co., Ltd.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuan Mi. Retrieved from https://idiyas.com/inventor/yuan-mi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 11)

% Patents Active = 52.2

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 14)

Average Co-Inventor Count = 8.8

ph-index = 6

Forward Citations = 129(Granted Patents)

Location History:

San Diego, CA (US) (2007 - 2012)
Shanghai, CN (2009 - 2024)

Company Filing History:

Cytosinlab Therapeutics Co., Ltd.

patent

4. 1 out of 1

Irm LLC, a Delware Limited Corporation

patent

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Pyrido-pyrazinyl Compounds

AZA-quinoline Compounds

Quinoline Compounds

Triazolopyrimidine Compounds

Triazolopyridine Compounds

Heterocyclic Oxime Compounds

Heterocyclic Hydrazone Compounds

Protein Kinase Inhibitors

Immunosuppressant Compounds

Bicyclic Compounds

Bis-aromatic Alkanols

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673947 - Pyrido-pyrazinyl compounds for treating acute myeloid leukemia (2026-07-07),

2. 12544374 - AZA-quinoline compounds and uses thereof (2026-02-10),

3. 12473273 - Quinoline compounds and compositions for inhibiting EZH2 (2025-11-18),

4. 11931363 - Triazolopyrimidine compounds and uses thereof (2024-03-19),

5. 11207325 - Triazolopyrimidine compounds and uses thereof (2021-12-28),

6. 10689378 - Triazolopyridine compounds and uses thereof (2020-06-23),

7. 10676479 - Imidazolepyridine compounds and uses thereof (2020-06-09),

8. 10220036 - Triazolopyrimidine compounds and uses thereof (2019-03-05),

9. 9580437 - Triazolopyrimidine compounds and uses thereof (2017-02-28),

10. 9474762 - Triazolopyridine compounds (2016-10-25),

11. 9062045 - Triazolopyridine compounds (2015-06-23),

12. 8507676 - Heterocyclic oxime compounds (2013-08-13),

13. 8497368 - Heterocyclic hydrazone compounds (2013-07-30),

14. 8410264 - Heterocyclic oxime compounds (2013-04-02),

15. 8101608 - Compounds and compositions as protein kinase inhibitors (2012-01-24),

Title: Yuan Mi - Innovator in Pharmaceutical Compounds

Introduction

Yuan Mi is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of pharmaceutical compounds. With an impressive portfolio of 20 patents, Yuan Mi has established himself as a key figure in the innovation landscape, particularly in the development of therapeutic agents.

Latest Patents

Among Yuan Mi's most recent patents are his innovative Triazolopyrimidine compounds. These compounds are characterized by a specific formula and exhibit potential in treating PRC2-mediated diseases or disorders. The detailed structure of these compounds indicates their role as a pharmaceutically acceptable salt, which emphasizes their utility in modern medicine.

Career Highlights

Yuan Mi has had a notable career with his involvement in leading pharmaceutical companies such as Novartis AG and Irm LLC. His work during these tenures has not only advanced his individual career but has also contributed to the broader field of medicinal chemistry.

Collaborations

Throughout his career, Yuan Mi has collaborated with esteemed colleagues, including Nathanael Schiander Gray and Zhengtian Yu. These partnerships have led to the exchange of valuable ideas, fostering advancements in research and the development of new pharmaceutical compounds.

Conclusion

Yuan Mi's work in the realm of Triazolopyrimidine compounds and his collaborations within the pharmaceutical industry underscore his role as an influential inventor. His ongoing commitment to research and innovation continues to pave the way for breakthroughs in the treatment of complex diseases.

Profile summary based on public USPTO records.